130 related articles for article (PubMed ID: 23446700)
1. A method for measurement of drug sensitivity of myeloma cells co-cultured with bone marrow stromal cells.
Misund K; Baranowska KA; Holien T; Rampa C; Klein DC; Børset M; Waage A; Sundan A
J Biomol Screen; 2013 Jul; 18(6):637-46. PubMed ID: 23446700
[TBL] [Abstract][Full Text] [Related]
2. Fluorescence-based experimental model to evaluate the concomitant effect of drugs on the tumour microenvironment and cancer cells.
Ramasamy K; Khatun H; Macpherson L; Caley MP; Sturge J; Mufti GJ; Schey SA; Calle Y
Br J Haematol; 2012 Jun; 157(5):564-79. PubMed ID: 22428569
[TBL] [Abstract][Full Text] [Related]
3. Lymphoma and myeloma cells are highly sensitive to growth arrest and apoptosis induced by artesunate.
Holien T; Olsen OE; Misund K; Hella H; Waage A; Rø TB; Sundan A
Eur J Haematol; 2013 Oct; 91(4):339-46. PubMed ID: 23869695
[TBL] [Abstract][Full Text] [Related]
4. Small molecule enhancers of rapamycin induce apoptosis in myeloma cells via GSK3A/B preferentially within a protective bone marrow microenvironment.
Nekova TS; Dotterweich J; Schütze N; Einsele H; Stuhler G
Br J Haematol; 2014 Oct; 167(2):272-4. PubMed ID: 24916065
[No Abstract] [Full Text] [Related]
5. Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms.
Nefedova Y; Landowski TH; Dalton WS
Leukemia; 2003 Jun; 17(6):1175-82. PubMed ID: 12764386
[TBL] [Abstract][Full Text] [Related]
6. The RANK/RANK ligand system is involved in interleukin-6 and interleukin-11 up-regulation by human myeloma cells in the bone marrow microenvironment.
Giuliani N; Colla S; Morandi F; Rizzoli V
Haematologica; 2004 Sep; 89(9):1118-23. PubMed ID: 15377473
[TBL] [Abstract][Full Text] [Related]
7. MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo.
Hideshima T; Neri P; Tassone P; Yasui H; Ishitsuka K; Raje N; Chauhan D; Podar K; Mitsiades C; Dang L; Munshi N; Richardson P; Schenkein D; Anderson KC
Clin Cancer Res; 2006 Oct; 12(19):5887-94. PubMed ID: 17020997
[TBL] [Abstract][Full Text] [Related]
8. The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells.
Maiso P; Ocio EM; Garayoa M; Montero JC; Hofmann F; García-Echeverría C; Zimmermann J; Pandiella A; San Miguel JF
Br J Haematol; 2008 May; 141(4):470-82. PubMed ID: 18341634
[TBL] [Abstract][Full Text] [Related]
9. FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance.
Yasui H; Hideshima T; Raje N; Roccaro AM; Shiraishi N; Kumar S; Hamasaki M; Ishitsuka K; Tai YT; Podar K; Catley L; Mitsiades CS; Richardson PG; Albert R; Brinkmann V; Chauhan D; Anderson KC
Cancer Res; 2005 Aug; 65(16):7478-84. PubMed ID: 16103102
[TBL] [Abstract][Full Text] [Related]
10. The bone marrow stromal environment is a major factor in myeloma cell resistance to dexamethasone.
Grigorieva I; Thomas X; Epstein J
Exp Hematol; 1998 Jul; 26(7):597-603. PubMed ID: 9657134
[TBL] [Abstract][Full Text] [Related]
11. Primary myeloma interaction and growth in coculture with healthy donor hematopoietic bone marrow.
Bam R; Khan S; Ling W; Randal SS; Li X; Barlogie B; Edmondson R; Yaccoby S
BMC Cancer; 2015 Nov; 15():864. PubMed ID: 26545722
[TBL] [Abstract][Full Text] [Related]
12. Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules.
Bolzoni M; Storti P; Bonomini S; Todoerti K; Guasco D; Toscani D; Agnelli L; Neri A; Rizzoli V; Giuliani N
Exp Hematol; 2013 Apr; 41(4):387-97.e1. PubMed ID: 23178378
[TBL] [Abstract][Full Text] [Related]
13. Translation of a tumor microenvironment mimicking 3D tumor growth co-culture assay platform to high-content screening.
Krausz E; de Hoogt R; Gustin E; Cornelissen F; Grand-Perret T; Janssen L; Vloemans N; Wuyts D; Frans S; Axel A; Peeters PJ; Hall B; Cik M
J Biomol Screen; 2013 Jan; 18(1):54-66. PubMed ID: 22923784
[TBL] [Abstract][Full Text] [Related]
14. Paclitaxel-releasing mesenchymal stromal cells inhibit the growth of multiple myeloma cells in a dynamic 3D culture system.
Bonomi A; Steimberg N; Benetti A; Berenzi A; Alessandri G; Pascucci L; Boniotti J; Coccè V; Sordi V; Pessina A; Mazzoleni G
Hematol Oncol; 2017 Dec; 35(4):693-702. PubMed ID: 27283119
[TBL] [Abstract][Full Text] [Related]
15. Bone marrow-derived mesenchymal stromal cells are attracted by multiple myeloma cell-produced chemokine CCL25 and favor myeloma cell growth in vitro and in vivo.
Xu S; Menu E; De Becker A; Van Camp B; Vanderkerken K; Van Riet I
Stem Cells; 2012 Feb; 30(2):266-79. PubMed ID: 22102554
[TBL] [Abstract][Full Text] [Related]
16. Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells.
Shipman CM; Croucher PI
Cancer Res; 2003 Mar; 63(5):912-6. PubMed ID: 12615702
[TBL] [Abstract][Full Text] [Related]
17. Mesenchymal stromal cells revert multiple myeloma cells to less differentiated phenotype by the combined activities of adhesive interactions and interleukin-6.
Dezorella N; Pevsner-Fischer M; Deutsch V; Kay S; Baron S; Stern R; Tavor S; Nagler A; Naparstek E; Zipori D; Katz BZ
Exp Cell Res; 2009 Jul; 315(11):1904-13. PubMed ID: 19328780
[TBL] [Abstract][Full Text] [Related]
18. BCL6 modulation of acute lymphoblastic leukemia response to chemotherapy.
Slone WL; Moses BS; Hare I; Evans R; Piktel D; Gibson LF
Oncotarget; 2016 Apr; 7(17):23439-53. PubMed ID: 27015556
[TBL] [Abstract][Full Text] [Related]
19. The polo-like kinase inhibitor BI 2536 exhibits potent activity against malignant plasma cells and represents a novel therapy in multiple myeloma.
Stewart HJ; Kishikova L; Powell FL; Wheatley SP; Chevassut TJ
Exp Hematol; 2011 Mar; 39(3):330-8. PubMed ID: 21184800
[TBL] [Abstract][Full Text] [Related]
20. An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells.
Silva A; Jacobson T; Meads M; Distler A; Shain K
J Vis Exp; 2015 Jul; (101):e53070. PubMed ID: 26274375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
